Timing of Anti-Snake Venom Administration and Clinical Outcomes in Snakebite Envenoming
International Journal of Pharmaceutical Quality Assurance · 30.11.2026 · 17 (11)
DOI: 10.25258/ijpqa.17.11.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.11.2026. Verfasst von J. Kamaraj und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Snakebite envenoming remains an important preventable cause of morbidity and mortality in tropical and subtropical regions, with rural agricultural populations disproportionately affected. The effectiveness of treatment depends substantially on rapid recognition, transport, appropriate first aid, timely administration of anti-snake venom (ASV), and supportive care. This study examined the relationship between bite-to-needle time (BNT), clinical complications, ASV use, treatment delays, and outcomes.
Methods
A retrospective-prospective observational design was used in this study done at a tertiary-care teaching hospital in 250 cases. Patients older than 12 years with confirmed snakebite who received ASV were included; pregnant and breastfeeding women were excluded. Demographic characteristics, first aid, suspected snake species, BNT, complications, ASV exposure, adverse events, reasons for delay, and clinical outcomes were analyzed. Categorical variables were summarized as frequency and percentage, and BNT-by-complication distribution was tested using chi-square analysis.
Results
In this study males accounted for 133 (53.2%) patients and females for 117 (46.8%). First aid was not received by 107 (42.8%) patients, while 85 (34.0%) received care at a primary health centre and 58 (23.2%) had tourniquets applied. BNT was ≤4 hours in 157 (62.8%), 4–8 hours in 61 (24.4%), 8–12 hours in 12 (4.8%), 1224 hours in 18 (7.2%), and >24 hours in 2 (0.8%). Complications were present in 194 (77.6%) cases and absent in 56 (22.4%). The proportion with complications increased from 65.6% in the ≤4-hour group to 96.7% in the 4–8-hour group and 100% in each later interval. The association between BNT and complications was statistically significant (χ²=35.06, df=4, p
Zitieren
APA
Kamaraj, J., Karthikeyan, N., & Ragavan, N. (2026). Timing of Anti-Snake Venom Administration and Clinical Outcomes in Snakebite Envenoming. International Journal of Pharmaceutical Quality Assurance, 17(11). https://doi.org/10.25258/ijpqa.17.11.5
Vancouver
Kamaraj J, Karthikeyan N, Ragavan N. Timing of Anti-Snake Venom Administration and Clinical Outcomes in Snakebite Envenoming. International Journal of Pharmaceutical Quality Assurance. 2026;17(11). doi:10.25258/ijpqa.17.11.5
BibTeX
@article{Kamaraj2026,
author = {Kamaraj, J. and Karthikeyan, N. and Ragavan, N.},
title = {Timing of Anti-Snake Venom Administration and Clinical Outcomes in Snakebite Envenoming},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {11},
doi = {10.25258/ijpqa.17.11.5}
}
EUVIMED